Hughes syndrome and epilepsy: when to test for antiphospholipid antibodies?
- Published in:
- Lupus, 2016, v. 25, n. 13, p. 1397, doi. 10.1177/0961203316651747
- By:
- Publication type:
- Article
Works matching IS 09612033 AND DT 2016 AND VI 25 AND IP 13
Results: 15
1
2
Ethnic differences in the epidemiology of cutaneous lupus erythematosus in New Zealand.
- Published in:
- Lupus, 2016, v. 25, n. 13, p. 1497, doi. 10.1177/0961203316651745
- By:
- Publication type:
- Article
3
A young male with more than lupus.
- Published in:
- 2016
- By:
- Publication type:
- Case Study
4
Correlation between the Modified Systemic Lupus Erythematosus Disease Activity Index 2000 and the European Consensus Lupus Activity Measurement in juvenile systemic lupus erythematosus.
- Published in:
- Lupus, 2016, v. 25, n. 13, p. 1479, doi. 10.1177/0961203316651737
- By:
- Publication type:
- Article
5
Lupus pneumonitis as the initial presentation of systemic lupus erythematosus: case series from a single institution.
- Published in:
- Lupus, 2016, v. 25, n. 13, p. 1485, doi. 10.1177/0961203316646461
- By:
- Publication type:
- Article
6
Revisiting an unsolved problem – impact of SLICC criteria on the risk of metabolic syndrome.
- Published in:
- Lupus, 2016, v. 25, n. 13, p. 1505, doi. 10.1177/0961203316644332
- By:
- Publication type:
- Article
7
A non-fatal pneumonia due to Legionella longbeachae in a patient with systemic lupus erythematosus.
- Published in:
- 2016
- By:
- Publication type:
- Case Study
8
The effects of corticosteroids on cognitive flexibility and decision-making in women with lupus.
- Published in:
- Lupus, 2016, v. 25, n. 13, p. 1470, doi. 10.1177/0961203316642313
- By:
- Publication type:
- Article
9
Association of estimated sodium and potassium intake with blood pressure in patients with systemic lupus erythematosus.
- Published in:
- Lupus, 2016, v. 25, n. 13, p. 1463, doi. 10.1177/0961203316642311
- By:
- Publication type:
- Article
10
Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
- Published in:
- Lupus, 2016, v. 25, n. 13, p. 1448, doi. 10.1177/0961203316642309
- By:
- Publication type:
- Article
11
Gastrointestinal manifestations in systemic lupus erythematosus.
- Published in:
- Lupus, 2016, v. 25, n. 13, p. 1456, doi. 10.1177/0961203316642308
- By:
- Publication type:
- Article
12
The rate of and risk factors for frequent hospitalization in systemic lupus erythematosus: results from the Korean lupus network registry.
- Published in:
- Lupus, 2016, v. 25, n. 13, p. 1412, doi. 10.1177/0961203316640916
- By:
- Publication type:
- Article
13
Disease activity and transition outcomes in a childhood-onset systemic lupus erythematosus cohort.
- Published in:
- Lupus, 2016, v. 25, n. 13, p. 1431, doi. 10.1177/0961203316640913
- By:
- Publication type:
- Article
14
Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease.
- Published in:
- Lupus, 2016, v. 25, n. 13, p. 1440, doi. 10.1177/0961203316640911
- By:
- Publication type:
- Article
15
Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus.
- Published in:
- Lupus, 2016, v. 25, n. 13, p. 1420, doi. 10.1177/0961203316640910
- By:
- Publication type:
- Article